Escherichia coli in septic arthritis: prevalence and antibiotics susceptibility patterns

大肠杆菌在化脓性关节炎中的流行情况和抗生素敏感性模式

阅读:1

Abstract

BACKGROUND AND OBJECTIVES: Septic arthritis (SA) is an orthopedic emergency mainly caused by bacteria. SA due to Escherichia coli (E. coli) is rare with a poor prognosis. This study aimed to assess the occurrence and antibiotic resistance patterns of E. coli in SA patients in Quetta, Balochistan, Pakistan. MATERIALS AND METHODS: A cross-sectional study was conducted from March 2021 to December 2023. 220 samples were collected from SA patients from tertiary care hospitals. Joint aspirates (2ml) and blood (5ml) were analyzed for microbial and hematological examination. RESULTS: There were 5.45% samples positive, and 94.5% negative for E. coli. SA due to E. coli was more common in male (6.2%) than female (4.6%) patients with the knee being the most affected joint (6.3%). E. coli was more common in patients aged 41-60 years (7.7%), lower socioeconomic (6.9%), and illiterate (8.6%) patients. Suspected patients showed a significant increase in the levels of white blood cells (WBC), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), notably, these levels were further elevated in E. coli-positive patients. The polymerase chain reaction (PCR) based identification of E. coli showed clear bands of 204bp of the 16S rRNA gene. Sequence analysis using the Basic Local Alignment Search Tool found high similarity with pathogenic E. coli from Egypt and China. The identified E. coli strain showed significant resistance to common antibiotics: amoxicillin, amoxicillin-clavulanate, ceftriaxone, sulfamethoxazole/trimethoprim, gentamicin, tetracycline, and erythromycin. CONCLUSION: Antibiotic resistance in E. coli from SA patients suggests the need for accurate antibiotic selection to ensure prompt treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。